Screener
Spyre Therapeutics, Inc. SYRE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued and other liabilities | 3,653 | (5,998) |
| Related party accounts payable | 36 | 1,945 |
| Prepaid expenses and other assets | (233) | 462 |
| Net cash used in operating activities | (57,372) | (40,994) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Proceeds from maturities and sales of marketable securities | 107,748 | 71,383 |
| Purchases of marketable securities | (81,167) | (71,444) |
| Proceeds from sale of in-process research and development asset | 30,000 | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s operating cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported operating cash flow of -$57.37M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s operating cash flow decreased by 40.0% year-over-year, from -$40.99M to -$57.37M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s operating cash flow has grown at a 32.0% compound annual growth rate (CAGR), from -$55.8M to -$169.25M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Spyre Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude